BRCAness profile of sporadic ovarian cancer predicts disease recurrence

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Wysham, Weiya Z ^a,b   Mhawech Fauceglia, Paulette ^c   Li, Hong ^b   Hays, Laura ^b   Syriac, Suzanna ^c   Skrepnik, Tijana ^d   Wright, Jay ^a   Pande, Nupur ^a,b   Hoatlin, Maureen ^b   Pejovic, Tanja ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; PROTEIN BRCA; PROTEIN P53; UNCLASSIFIED DRUG; BRCA2 PROTEIN; FANCD2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SPORADIC OVARIAN CANCER; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA REPAIR ENZYMES; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855698070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030042     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics 2009. CA Cancer J Clin 59 (4): 225-49.
2. Bast RC, Mills GB, (2010) Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28 (22): 3545-58.
3. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, et al. (2003) Improved survival in women with BRCA associated ovarian carcinoma. Cancer 97: 2187-2195.
4. Cannistra SA, (2004) Cancer of the ovary. N Engl J Med 351 (24): 2519-29.
5. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, et al. (2008) "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26 (34): 5530-6.
6. O'Brien T, Stokoe D, (2009) Converting cancer mutations into therapeutic opportunities. EMBO Mol Med 1 (6-7): 297-9.
7. Chioh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL, (2011) The role of poly adenosisne diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia-Pacific JCO 7: 197-211.
8. Kontationopoulos PA, Spentoz D, Karlan BY, Taniguchi T, Fountzilaz E, et al. (2010) Gene Expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28: 3555-3561.
9. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361 (2): 123-34.
10. Audeh MW, Penson RT, Friedlander M, et al. (2009) Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA deficient advanced ovarian cancer. J Clin Oncol 27: 277s (suppl; abstr 5500).
11. Tutt A, Robson M, Garber JE, Domchek SM, Weitzel JN, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376 (9737): 235-44.
12. Serov S F, Scully RE, Sobin LH, (1973) Histological typing of ovarian tumors. International Classification of Tumors, Vol. 9, WHO Geneva.
13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (7): 844-7.
14. Kalbfleisch J, Prentice R, (2002) The statistical analysis of failure time data (2nd edition). Hoboken, NJ.
15. Tan DS, Rothermundt C, Thomas K, (2008) "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26: 5530-6.
16. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, et al. (2010) Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28: 357-6.
17. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, et al. (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9 (5): 568-74.
18. Pejovic T, Yates JE, Liu HY, Hays LE, Akkari Y, et al. (2006) Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. Cancer Res 66: 9017-25.
19. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, et al. (2007) Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117 (5): 1440-9.
20. Rhiem K, Todt U, Wappenschmidt B, Klein A, Wardelmann E, et al. (2010) Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Res 30 (9): 3445-9.
21. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, et al. (2010) PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2 (53): 53ra75.
22. Salmena L, Carracedo A, Pandolfi PP, (2008) Tenets of PTEN tumor suppression. Cell 133 (3): 403-14.
23. Brustmann H, (2007) Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol 26 (2): 147-53.
24. Parija S, Kumar A, (2011) A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer. Int J Bioinform Res Appl 7: 1-14.
25. Köbel M, Reuss A, Bois A, Kommoss S, Kommoss F, et al. (2010) The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010 Oct, 222 (2): 191-8.
26. Skytte A-B, Waldsterom M, Rasmussen AA, Cruger D, Woodward ER, et al. (2011) Identification of BRCA-1 deficient ovarian cancers. ACTA Ostet Gynecol 90: 593-599.25.
27. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinoma. Nat genet 21: 236-240.
28. Al-Mulla, Abdulrahman M, Varadharaj G, Akhter N, Anim JT, (2005) BRCA1 Gene expression in breast cancer: A correlative study between real-time RT-PCR and immunohistochemistry. 53: 621-629.
29. Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, et al. (2011) Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol doi:10.1093/annonc/mdq770.
30. Birrer MJ, Konstatinopoulos P, Penson RT, Roche M, Ambrosio A, et al. (2011) Aphase II trial of iniparib (BSI-201) in combination with gemcitibine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol 29: suppl; abstr 5005.
31. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006 5: 952-61.